EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

被引：0
|
作者：
Dinh, M. [1 ]
Pithavala, Y. [1 ]
Chen, J. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-053
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [41] Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
    Besse, Benjamin
    Solomon, Benjamin J.
    Felip, Enriqueta
    Bauer, Todd Michael
    Ou, Sai-Hong Ignatius
    Soo, Ross A.
    Camidge, D. Ross
    Chiari, Rita
    Gadgeel, Shirish M.
    Riely, Gregory J.
    Tan, Eng Huat
    Hayashi, Hidetoshi
    Mazieres, Julien
    Thurm, Holger C.
    Martini, Jean-Francois
    Abbattista, Antonello
    Peltz, Gerson
    Clancy, Jill S.
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [43] COST-EFFECTIVENESS OF LORLATINIB IN SECOND-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, S.
    Jiang, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S201 - S201
  • [44] A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
    Shih, J. -Y.
    Luo, Y. -H.
    Chang, G. -C.
    Chang, J. W. -C.
    Wang, C. -C.
    Yang, T.
    Fang, W.
    Shau, W. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S475 - S475
  • [45] EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
    Ferreira, Carlos G.
    Barrios, C.
    Shaw, Alice T.
    Shi, Yuankai
    De Pas, Tommaso M.
    Yang, Pan C.
    Riely, Greg J.
    Crino, Lucio
    Iyer, Shrividya
    Polli, Anna
    Lanzalone, Silvana
    Kim, Dong W.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S108
  • [46] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [47] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [48] Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
    Solomon, B.
    Bauer, T. M.
    De Marinis, F.
    Felip, E.
    Goto, Y.
    Liu, G.
    Mazieres, J.
    Kim, D-W.
    Mok, T.
    Polli, A.
    Thurm, H.
    Calella, A. M.
    Peltz, G.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1180 - S1181
  • [49] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients
    Horn, Leora
    Reckamp, Karen L.
    Patel, Sandip
    Blumenschein, George
    Neal, Joel W.
    Gitlitz, Barbara
    Waqar, Saiama
    Oxnard, Geoffrey
    Brzezniak, Christina
    Dukart, Gary
    Tan, Fenlai
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Wakelee, Heather A.
    CANCER RESEARCH, 2017, 77
12345